Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Plans on Emergency Use Access

by rvvadmin | Dec 23, 2020 | 2020

TORONTO, Dec. 23, 2020 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update...

Revive Therapeutics Announces LOI to Acquire PharmaTher’s Psilocybin Program

by rvvadmin | Dec 21, 2020 | 2020

TORONTO, Dec. 21, 2020 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it...

Binding of SARS-CoV-2 spike protein to ACE2 is disabled by thiol-based drugs; evidence from in vitro SARS-CoV-2 infection studies.

by rvvadmin | Dec 14, 2020 | 2020

View...

Epidemiologist Dr. Joel Moody Joins Revive Therapeutics as Medical and Clinical Advisor

by rvvadmin | Dec 2, 2020 | 2020

TORONTO, Dec. 02, 2020 – Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the appointment of Dr....

Revive Therapeutics Announces Research Collaboration with PharmaTher for Development of Psilocybin in Cancer and Discovery of Novel Uses of Psychedelics

by rvvadmin | Nov 20, 2020 | 2020

TORONTO, Nov. 18, 2020 – Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce it has entered into an...